We previously observed that treating an in vivo model of HER2+ breast cancer with 10 mg/kg trastuzumab prior to doxorubicin significantly improved tumor vascular delivery and sensitized the tumor to chemotherapy [23], therefore significantly altering sustained tumor burden long after therapy was stopped. Here, ERBB2 is linked to neoplasm.